Navigation Links
Wound Management Technologies, Inc. Announces Negotiations to Acquire BioPharma Management Technologies, Inc.
Date:12/11/2008

FORT WORTH, Texas, Dec. 11 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), announced today that it is exploring a potential acquisition of BioPharma Management Technologies, Inc., a company that has recently launched the development of topical pain management products. "While we have been focusing this year on expanding market penetration of our CellerateRx(R) products, we also have been working to expand our current product portfolio. We believe that the science behind BioPharma's product development shows potential and creates market synergies with our current products," says Scott Haire, Wound Management Technologies' CEO. "We believe that BioPharma's products will provide a broad application across several medical specialities. We are not aware of any currently available products in the market that provide the benefits we expect BioPharma's unique formulation to deliver."

BioPharma is developing a topical pain management product targeting the growing pain management market place. "Based on our research, we believe that this product will provide a broad application across several medical specialities while supplying a good safety profile, expanded dosing range and flexibility, and should create and maintain a moist environment conducive to drug absorption and reduction of irritation at the application site. All year we have focused on Cellerate as a one-of-a-kind product and adding an additional company and product mix should make us a leader in the wound industry and related healthcare markets," states Scott Haire, CEO of Wound Management Technologies. "Also this should significantly increase our revenues in 2010 in all areas of wound care."

CellerateRx(R) is exclusively distributed by Wound Care Innovations, a subsidiary of Wound Management Technologies. It is a one-of-a-kind, patented, advanced wound care collagen product and is FDA cleared for acute and ch
'/>"/>

SOURCE Wound Management Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Life-Saving News for Battlefield Soldiers & Wounded Civilians
2. LifeNet Health Establishes The Skin & Wound Allograft Institute
3. Operation Mend Offers New Hope for Wounded Warriors
4. PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade(TM)
5. Remarks by President Bush, Senator Bob Dole and Secretary Donna Shalala on Commission on Care for Americas Returning Wounded Warriors Report Implementation
6. Patients should ask surgeons about using honey to heal wounds
7. The USO and CarePages.com Help Wounded Troops Stay Connected to Their Families
8. Trends in Treatment of Americas Wounded Warriors
9. Report Release: Trends in Treatment of Americas Wounded Warriors
10. Innocoll Receives Intends to Grant Notices from the European Patent Office for Two European Patent Applications Related to Novel Wound Healing, Biosurgery and Drug Delivery Applications of its CollaRx(R) Technology
11. Randy Travis Participates in American Red Cross Holiday Card Program to Wounded Service Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... of your worst memories? How did it make you ... a negative personal experience, such as how sad you ... emotional distress, especially when you can,t stop thinking about ... thinking about the context of the memories, rather than ... way to alleviate the negative effects of these memories, ...
(Date:4/18/2014)... available in French . ... practice and regenerative medicine. A team led by Ludwik ... Paris Tech) and Didier Letourneur from the Laboratoire Recherche ... just demonstrated that the principle of adhesion by aqueous ... repair soft-tissue organs and tissues. This easy-to-use gluing method ...
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
(Date:4/17/2014)... the April issue of Experimental Biology and ... Drs. Rex Gaskins and Paul Kenis in the ... of the University of Illinois Urbana-Champaign describe their ... reactions underlie a variety of cell functions including ... these crucial roles in regulating normal cellular behavior, ...
(Date:4/17/2014)... Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently ... issue of Nature Reviews Microbiology , one ... McCullers, a world-renowned infectious disease specialist, and chair ... of Tennessee Health Science Center, analyzed the epidemiology ... and 1968 pandemics, as well as more recent ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... now widespread in just one state, but a resurgence could ... -- As the H1N1 swine flu outbreak eases to ... state, federal health officials are still urging Americans to get ... Influenza Vaccination Week," Kathleen Sebelius, Secretary of the U.S. Department ...
... , NEWBURGH, N.Y., Jan. 8 "I hope I ... need help and to offer them advice and guidance." , So said ... Mary College, is one of the many students who have made psychology ... Mount also has many students who pursue careers in education, taking a ...
... treatment with the natural compound Quercetin , FRIDAY, Jan. ... that play an important role in hepatitis C infection, and ... toxic treatments for the disease, which can lead to cirrhosis ... are interferon and ribavirin, which can cause major side effects ...
... , , - Subtle Language ... PHILADELPHIA, Jan 8 Children with autism spectrum disorders (ASDs) process ... without ASDs, and measuring magnetic signals that mark this delay may ... http://www.newscom.com/cgi-bin/prnh/20100108/DC34671 ) , Researchers at The Children,s Hospital of ...
... Jan. 8 Gilbert Hospital continued to exceed expectations in ... emergency department, patient levels remained constant compared to 2008. ... continued its success with more than 98.5% of emergency room ... minutes of arrival. Additionally, the average wait time in 2009 ...
... ... to be presented at 32nd annual San Antonio Breast Cancer Symposium , ... Los Angeles, ... biotechnology company, today announced that multiple clinical studies of the chemotherapy agent ABRAXANE® ...
Cached Medicine News:Health News:As Swine Flu Ebbs, Officials Stress Importance of Vaccine 2Health News:As Swine Flu Ebbs, Officials Stress Importance of Vaccine 3Health News:Psychology Popular Among College Students 2Health News:Psychology Popular Among College Students 3Health News:Psychology Popular Among College Students 4Health News:Psychology Popular Among College Students 5Health News:Key to Hepatitis C May Be Two Cellular Proteins 2Health News:Brain Imaging May Help Diagnose Autism 2Health News:Brain Imaging May Help Diagnose Autism 3Health News:Brain Imaging May Help Diagnose Autism 4Health News:Gilbert Hospital 2009 Emergency Department Year in Review 2Health News:Abraxis Provides Overview Of ABRAXANE Study 2Health News:Abraxis Provides Overview Of ABRAXANE Study 3
(Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
(Date:1/14/2014)... Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a ... it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... terms of the acquisition were not disclosed. ... providing a wide range of sleep, mobility, and respiratory products ...
(Date:1/14/2014)... 2014   Oligomerix, Inc. , a privately held company ... disease (AD) and related neurodegenerative disorders, announced today the ... NY as of January 15, 2014 and ... York Medical College. Oligomerix, which is focused ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Homeostasis Effects in,Normal and Diabetic Rats --, CHICAGO, ... IIa study of the safety profile of multiple ... of,the Sodium-Glucose Transporter 2 (SGLT2) administered alone or,concomitantly ... no,discontinuations due to adverse events and no serious ...
... June 25, 2007 /PRNewswire/ -- Novagali Pharma, an,emerging ... its pivotal phase III clinical trial,positive results from ... suffering from Vernal Keratoconjunctivitis (VKC) at the,XIV Afro-Asian ... 25 2007 in Marrakech (Morocco). , VKC is ...
Cached Medicine Technology:First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 2First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 3First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 4First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 5First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 6Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 2Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 3Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 4
Inquire...
Inquire...
... remarkable anti-reflux valve is enclosed ... which prevents the valve from ... in sitting or reclining positions. ... and interference free ensuring uninterrupted ...
... anti-reflux valve is enclosed in ... prevents the valve from being ... sitting or reclining positions. The ... interference free ensuring uninterrupted flow ...
Medicine Products: